Article
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Clinical lung cancer - 1 Nov 2015
Lv Chao, An Chao, Feng Qin, Ma Yuanyuan, Li Shaolei, Wang Jia, Zhang Jianzhi, Wang Xing, Yan Shi, Fang Jian, Wang Yinxiang, Tan Fenlai, Yang Yue
Abstract excerpt
UNLABELLED: We retrospectively reviewed a total of 257 stage I to IIIa lung adenocarcinoma after resection, tested them for the epidermal growth factor receptor (EGFR) mutation, and analyzed the effect of perioperative treatment on survival. The results showed that in patients with an EGFR mutation, adjuvant EGFR-tyrosine kinase inhibitor monotherapy after complete resection significantly prolongs disease-free...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
